vs
Side-by-side financial comparison of Oportun Financial Corp (OPRT) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Oportun Financial Corp is the larger business by last-quarter revenue ($247.7M vs $129.7M, roughly 1.9× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -1.3%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -0.5%).
Oportun Financial Corp is a US-based fintech firm that provides accessible, responsible financial services including personal loans, credit cards, and savings products to underserved low-to-moderate income consumers, many with limited or no credit history, leveraging proprietary AI underwriting to deliver fair terms while mitigating operational risk.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
OPRT vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.7M | $129.7M |
| Net Profit | $3.4M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | 2.6% | -25.0% |
| Net Margin | 1.4% | — |
| Revenue YoY | -1.3% | 73.4% |
| Net Profit YoY | -61.0% | — |
| EPS (diluted) | $0.07 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.7M | $129.7M | ||
| Q3 25 | $238.7M | $164.9M | ||
| Q2 25 | $234.3M | $114.4M | ||
| Q1 25 | $235.9M | $81.7M | ||
| Q4 24 | $250.9M | $74.8M | ||
| Q3 24 | $250.0M | $62.9M | ||
| Q2 24 | $250.4M | $54.1M | ||
| Q1 24 | $250.5M | $41.4M |
| Q4 25 | $3.4M | — | ||
| Q3 25 | $5.2M | $25.7M | ||
| Q2 25 | $6.9M | $-12.8M | ||
| Q1 25 | $9.8M | $-41.2M | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $-30.0M | $-54.8M | ||
| Q2 24 | $-31.0M | $-70.4M | ||
| Q1 24 | $-26.4M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | 2.6% | -25.0% | ||
| Q3 25 | 6.0% | 15.1% | ||
| Q2 25 | 4.3% | -11.1% | ||
| Q1 25 | 5.6% | -52.2% | ||
| Q4 24 | 89.6% | -81.2% | ||
| Q3 24 | -15.8% | -89.3% | ||
| Q2 24 | -19.6% | -125.1% | ||
| Q1 24 | -12.2% | -336.5% |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 2.2% | 15.6% | ||
| Q2 25 | 2.9% | -11.1% | ||
| Q1 25 | 4.1% | -50.4% | ||
| Q4 24 | 200.1% | — | ||
| Q3 24 | -12.0% | -87.1% | ||
| Q2 24 | -12.4% | -130.1% | ||
| Q1 24 | -10.6% | -328.9% |
| Q4 25 | $0.07 | $0.04 | ||
| Q3 25 | $0.11 | $0.28 | ||
| Q2 25 | $0.14 | $-0.14 | ||
| Q1 25 | $0.21 | $-0.47 | ||
| Q4 24 | $0.26 | $-0.71 | ||
| Q3 24 | $-0.75 | $-0.70 | ||
| Q2 24 | $-0.78 | $-0.91 | ||
| Q1 24 | $-0.68 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $105.5M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $390.1M | $114.8M |
| Total Assets | $3.3B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $105.5M | $93.0M | ||
| Q3 25 | $104.6M | $110.9M | ||
| Q2 25 | $96.8M | $75.2M | ||
| Q1 25 | $78.5M | $61.9M | ||
| Q4 24 | $60.0M | $58.5M | ||
| Q3 24 | $71.8M | $36.4M | ||
| Q2 24 | $72.9M | $32.3M | ||
| Q1 24 | $69.2M | $43.3M |
| Q4 25 | $390.1M | $114.8M | ||
| Q3 25 | $383.9M | $73.6M | ||
| Q2 25 | $376.0M | $32.7M | ||
| Q1 25 | $366.1M | $32.8M | ||
| Q4 24 | $353.8M | $59.1M | ||
| Q3 24 | $327.6M | $-30.5M | ||
| Q2 24 | $354.1M | $15.1M | ||
| Q1 24 | $382.0M | $74.1M |
| Q4 25 | $3.3B | $605.2M | ||
| Q3 25 | $3.2B | $538.6M | ||
| Q2 25 | $3.2B | $555.3M | ||
| Q1 25 | $3.2B | $548.8M | ||
| Q4 24 | $3.2B | $594.1M | ||
| Q3 24 | $3.3B | $504.4M | ||
| Q2 24 | $3.3B | $551.1M | ||
| Q1 24 | $3.3B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $413.4M | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 121.45× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $413.4M | $60.7M | ||
| Q3 25 | $99.0M | $14.3M | ||
| Q2 25 | $104.5M | $5.0M | ||
| Q1 25 | $101.0M | $-42.2M | ||
| Q4 24 | $393.5M | $-35.7M | ||
| Q3 24 | $108.5M | $-42.5M | ||
| Q2 24 | $107.7M | $-40.2M | ||
| Q1 24 | $85.9M | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | 121.45× | — | ||
| Q3 25 | 19.05× | 0.56× | ||
| Q2 25 | 15.20× | — | ||
| Q1 25 | 10.34× | — | ||
| Q4 24 | 45.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OPRT
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
